Breast and Ovarian Cancer Program (BOCP) The mission of the Breast and Ovarian Cancer Program (BOCP), a newly established Program being proposed in this UPCI Cancer Center Support Grant renewal, is to reduce the incidence and death from women's cancer with a focus on breast and ovarian malignancies. This mission is achieved through the development and fostering of basic, translational, and clinical research in breast and ovarian cancer and aimed at translating novel discoveries into improved patient care. The BOCP has four main research themes: 1) basic cancer biology, 2) diagnostic and prognostic markers, 3) prevention, and 4) molecular therapeutics. The BOCP specific aims are to: 1) investigate mechanisms of cancer initiation and progression, 2) identify and validate new diagnostic and prognostic markers, 3) examine the role of tumor evolution and heterogeneity in progression and response to therapy, 4) discover the phenotypic and genotypic dependencies of metastatic cancer, and 5) translate knowledge of the biology into personalized prevention and treatment. The BOCP has 42 members representing 12 academic departments and 3 schools of the University of Pittsburgh. Based upon a retrospective analysis of historical data from January 2010 to April 2014, BOCP members authored or co- authored 517 cancer-related publications, of which 31% resulted from intra-programmatic and 30% from inter- programmatic collaborations. Approximately 54% of the papers represent collaborations with external investigators. Research in the BOCP is supported by an NCI Specialized Program of Research Excellence (SPORE) in Ovarian Cancer shared with Roswell Park Cancer Institute (RPCI), as well as individual federal grants, foundation awards, and philanthropy. BOCP members currently receive a total of $8.2 M in annual direct funding, including $2.6 M from the NCI and $2.1 M in other peer-reviewed grant support. A highly collaborative and interactive group, BOCP members meet regularly at work-in-progress meetings, journal clubs, and a yearly retreat. In addition, the BOCP forges relationships with other programs to enhance the multi-disciplinary nature of breast and ovarian cancer research at UPCI. UPCI support, including Clinical Protocol and Data Management and Shared Resources, specifically the Animal Facility, Biostatistics Facility, Cancer Bioinformatics Services, Cancer Genomics Facility, Cancer Pharmacokinetics and Pharmacodynamics Facility, Cancer Proteomics Facility, Cell and Tissue Imaging Facility, Chemical Biology Facility, Cytometry Facility, Immunological Monitoring and Cellular Products Laboratory, In Vivo Imaging Facility, Investigational Drug Services, and Tissue and Research Pathology Services facilitates and enhances BOCP research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-29
Application #
9324849
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
29
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478
Menk, Ashley V; Scharping, Nicole E; Moreci, Rebecca S et al. (2018) Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Rep 22:1509-1521
Redner, Robert L; Beumer, Jan H; Kropf, Patricia et al. (2018) A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma 59:2595-2601
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72
Frahm, Krystle A; Waldman, Jacob K; Luthra, Soumya et al. (2018) A comparison of the sexually dimorphic dexamethasone transcriptome in mouse cerebral cortical and hypothalamic embryonic neural stem cells. Mol Cell Endocrinol 471:42-50
Pulopulos, Matias M; Vanderhasselt, Marie-Anne; De Raedt, Rudi (2018) Association between changes in heart rate variability during the anticipation of a stressful situation and the stress-induced cortisol response. Psychoneuroendocrinology 94:63-71
Shiffman, Saul; Scholl, Sarah M (2018) Three approaches to quantifying cigarette consumption: Data from nondaily smokers. Psychol Addict Behav 32:249-254
Samuelsson, Laura B; Bovbjerg, Dana H; Roecklein, Kathryn A et al. (2018) Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review. Neurosci Biobehav Rev 84:35-48
Chen, Dongshi; Ni, Hong-Min; Wang, Lei et al. (2018) PUMA induction mediates acetaminophen-induced necrosis and liver injury. Hepatology :

Showing the most recent 10 out of 1187 publications